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Abstract: Brain and spinal cord traumas include blunt and penetrating trauma, disease, and 
required surgery. Such traumas trigger events such as inflammation, infiltration of inflammatory 
and other cells, oxidative stress, acidification, excitotoxicity, ischemia, and the loss of calcium 
homeostasis, all of which cause neurotoxicity and neuron death. To prevent trauma-induced 
neurological deficits and death, each of the many neurotoxic events that occur in parallel or 
sequentially must be minimized or prevented. Although neuroprotective techniques have been 
developed that block single neurotoxic events, most provide only limited neuroprotection and are 
only applied singly. However, because many neurotoxicity triggers arise from common events, 
an approach for invoking more effective neuroprotection is to apply multiple neuroprotective 
methods simultaneously before the many neurotoxic triggers and cascades are initiated and 
become irreversible. This paper first discusses some triggers of neurotoxicity and neuroprotec-
tive mechanisms that block them, including hypothermia, alkalinization, and the administration 
of adenosine. It then examines how the simultaneous application of these techniques provides 
significantly greater neuroprotection than is provided by any technique alone. The paper also 
stresses the importance of determining whether the neuroprotection provided by these techniques 
can be further enhanced by combining them with additional techniques, such as the systemic 
administration of glucocorticoids. Finally, the paper stresses the absolute critical importance of 
applying these techniques within the “golden hour” following trauma, before the many neurotoxic 
events and cascades are manifest and before the neurotoxic cascades become irreversible.
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Introduction
Brain and spinal cord traumas leading to neurotoxicity and neurological deficits include 
blunt and penetrating wounds, infections, and required surgeries that cause prolonged 
ischemia. Each of these insults triggers a complex cascade of secondary processes 
in the injured tissue, which results in a greatly enlarged secondary loss of tissue.1 
 Secondary causes of neurotoxicity include ischemia,2 the immediate result of disrupted 
blood flow,3 lipid peroxidation,4 oxidative stress,5 acidification,6 and inflammation.3 
In addition, a multitude of cellular and gene events take place as a consequence of 
trauma, each of which has to be survived to provide neuroprotection.
Even small changes in the pH (predominantly decreases in pH) result in dramatic 
changes in membrane properties that damage and kill neurons.7 Thus, acidifica-
tion caused by ischemia leads to more extensive acidification due to the excessive 
release of excitatory amino acids (EAAs),8 which accumulate in the extracellular 
space, causing further extracellular acidification and inducing both necrotic and 
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apoptotic neuron loss.8 Because certain neurons contain 
and release the EAAs glutamate and aspartate and have 
receptors for glutamate, the neurotoxic effect of the released 
  glutamate is exacerbated because glutamate stimulates its 
own release in a positive feedback loop by its interaction 
with   non-N-methyl-D-aspartic acid (NMDA) receptor 
subtypes.8 This in turn opens calcium ion channels, which 
allows a massive influx of extracellular calcium9 and causes 
a disruption in neurons’ calcium homeostasis,10–12 leading 
to neuron death. Finally, calcium-induced calcium release 
and the further influx of calcium through voltage-gated 
calcium channels after glutamate-induced depolarization 
contribute to glutamate toxicity. Thus, a multitude of events 
and cascades are triggered, which lead to an ever-increasing 
neurotoxic environment and result in neurological losses and, 
  eventually, death.
Trauma associated with even small   physiologically   relevant 
increases in temperature (2°C) causes   neuron death.13–15 The 
neurotoxicity is due to the release by   microglia-like and 
astrocytic cells of monocyte   chemotactic protein-1 and the 
generation of reactive oxygen intermediates.14
Brain and spinal cord insults also trigger additional 
  cascades of events that cause neurotoxicity by slightly differ-
ent mechanisms, such as through an inflammatory response,16 
in which neutrophils and some lymphocytes are recruited 
into the injured cat, rat, and mouse spinal cord.17 Activated 
macrophages/microglia are also recruited.18 In stroke, the 
resulting hypoxia triggers the production   microglia to 
release interleukin-1 and tumor necrosis factor-α,19 which 
kill neurons through an apoptotic mechanism.20 Within an 
injured area of the spinal cord, trauma also triggers the rapid 
expression of proinflammatory cytokines by endothelial 
cells and resident microglia.21 However, it remains unclear 
whether in addition to their beneficial functions neutrophils 
and microglia may also have harmful toxic effects for the 
surrounding healthy spinal cord tissue.
Inflammation is one of the early events triggered by trauma 
and includes the infiltration of the trauma site by monocytes 
that release molecules that are both neurotoxic and inhibit 
axon regeneration.22 Therefore, currently, the most favored 
early intervention following central nervous system (CNS) 
injury is to antagonize or control the post injury inflammatory 
process using pharmaceutical agents. Among those holding 
promise in improving patient outcomes   following brain and 
spinal cord injuries are   broad-spectrum immunosuppressive 
drugs (eg, minocycline), growth factors (eg, erythropoietin), 
dual anti-inflammatory and antivasospasm drugs such as 
Rho and ROCK kinase   inhibitors, and broad-spectrum 
  anti-inflammatory drugs such as PDE4 inhibitors.23 However, 
the current gold standard of acute care for spinal cord injury 
is the administration of high doses of glucocorticoids such 
as methylprednisolone and pregabalin within 8 hours of 
injury.24 Their administration more than 8 hours post trauma 
may be without effect or may be detrimental to the outcome 
of the patient.23
New neurotoxic pathways and mechanisms by which 
to block them are constantly being discovered. For 
example, oxidative stress-induced neurotoxicity can be 
blocked with cinnamophilin, a potent antioxidant and 
free-radical   scavenger with anti-inflammatory actions, 
which reduces acute ischemic brain damage when given 
up to 6 hours post ischemic insult.25 In addition, blocking 
microglial activation-induced   neurotoxicity with urocortin, 
a member of the   corticotropin-releasing hormone family of 
  neuropeptides, regulates stress responses, thus providing 
neuroprotection.26
By knowing the identity of the many cellular and 
  molecular triggers that cause trauma-induced neurotoxic 
cascades, different techniques can be applied one by one to 
block each of the triggers as it occurs. However, a simpler 
approach, and one that would provide even more enhanced 
neuroprotection, is to apply several broad-based neuroprotec-
tive techniques (hypothermia, alkalinization, administration 
of adenosine) simultaneously as soon as possible following 
trauma, when they can block the causes to the multiple 
  neurotoxic cascades before they are triggered or at least 
before they become irreversible.
This review first examines specific causes and   mechanisms 
of trauma-induced neurotoxicity and then looks at differ-
ent techniques that block each trigger of neurotoxicity. It 
  concludes by examining several methods that individually 
provide good neuroprotection but which when combined pro-
vide significantly greater neuroprotection by acting to prevent 
multiple neurotoxic triggers with overlapping mechanisms.
Neurotoxicity
Ischemia
Cerebral ischemia and head trauma lead to excitotoxicity and 
oxidative stress, which are major triggers of   neurotoxicity. 
Although their neurotoxicity is initiated differently, most of 
their neurotoxic mechanisms are the same.   Excitotoxic- and 
oxidative stress-induced neurotoxicity are linked because 
both are associated with neuron exposure to excess   glutamate, 
which in turn causes a large increase in extracellular 
  glutamate and intracellular calcium, acidosis, elevated potas-
sium, activation of proteases, synthesis of nitric oxide (NO), 
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and production of reactive oxygen species (ROS), which 
contribute to neurotoxicity.27
Excitotoxicity
Excitotoxicity involves two mechanisms related to the 
  cytotoxic effects of glutamate: (1) intense stimulation of 
NMDA receptors, which can be generated by only 5 minutes of 
exposure to glutamate, causing death within 12–24 hours;28 and 
(2) non-NMDA receptor-mediated excitotoxicity, which takes 
more than 1 hour of exposure to induce a lethal stimulus.
Ischemia-induced excitotoxicity is neurotoxicity   triggered 
by (1) excess release and extracellular accumulation of EAAs 
and excitotoxins such as glutamate and aspartate, which 
many neurons contain and release29 and for which they have 
receptors;30 (2) lipid peroxidation;4 and (3) trauma-induced 
inflammation.3 The extent of the increased extracellular 
  glutamate concentration is related to the severity of the 
trauma, which in turn is directly related to the severity of 
the neurotoxicity and neuron death.31 Neuron exposure to an 
excessive concentration of extracellular EAAs leads to the 
excessive stimulation of their NMDA subtype of   glutamate 
receptors and the development of a neurotoxic level of extra-
cellular acidification (pH 7.3–6.5), with the extent of neuron 
death being related to the degree and   duration of acidosis.32
Excessive glutamate release stimulates further   glutamate 
release in a positive feedback loop by interacting with 
  non-NMDA receptor subtypes32 and causing receptor 
  activation. The acidification caused by the glutamate 
leads to the opening of receptor-coupled N-type voltage-
sensitive calcium channels, which allow further excessive 
entry of extracellular calcium into neurons.9 This elevated 
  calcium then causes the loss of calcium homeostasis, which 
  disrupts mitochondrial function and electron transport chain 
  dysfunction and causes neuron death.33
Glutamate receptor antagonists such as the   noncompetitive 
NMDA receptor antagonist dextrophan or the competitive 
antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic 
acid block a portion of the triggered neuronal toxicity and 
death. These data suggest that glutamate neurotoxicity and the 
subsequent degenerative processes are predominantly medi-
ated by the activation of the NMDA subclass of   glutamate 
receptors, occurring both directly during exposure to exog-
enous compounds and indirectly via the subsequent release 
of endogenous NMDA agonists.34
Oxidative stress
Oxidative stress is the result of the production of ROS such 
as superoxide anion, hydroxyl radical, and hydrogen peroxide 
(H2O2), which are produced during the process of neuronal 
death.35 Oxidative stress represents an imbalance between 
the production and manifestation of ROS and a biological 
system’s ability to detoxify the reactive intermediates or to 
repair the resulting damage they cause.
Oxidative stress is exemplified by the actions of   potassium 
cyanide, which initiates neurotoxicity as a rapidly acting 
mitochondrial poison that inhibits cellular respiration and 
energy metabolism (glycolysis), and also by causing extra-
cellular acidification and the loss of calcium homeostasis.36 
This leads to histotoxic hypoxia, a significant depletion of 
mitochondrial glutathione (diminished cellular antioxidant 
system),37 increased H2O2 generation,38 which is accompanied 
by lipid peroxidation, and generation of ROS and reactive 
nitrogen species, which damage all components of the cell, 
including proteins, lipids, and DNA. The effect of oxidative 
stress depends upon the magnitude of these changes, but cell 
death is initiated by apoptosis39 and necrosis.40
At excitotoxic concentrations, glutamate rapidly produces 
ROS by a process involving NMDA receptor activation and 
calcium entry through the NMDA receptors.41 This   suggests 
that ROS production is an early event in   glutamate-induced 
neuronal injury. This toxicity can be blocked by the 
  mitochondrial proton ionophore carbonyl cyanide   ptrifluo
romethoxyphenylhydrazone, suggesting that ROS produc-
tion also occurs due to calcium uptake into mitochondria41 
and intracellular acidification.41 These studies suggest that 
mitochondria play a critical role in the production of ROS 
in association with glutamate excitotoxicity.
The application of antioxidants such as the   21-aminosteroid 
tirilizad can partially protect cultured neurons from NMDA 
receptor-mediated cell injury.42 Techniques that offer neuro-
protection against excitotoxicity can be protective against 
oxidative stress and vice versa.
Acidosis
Acidosis is a universal tissue response to ischemia-induced 
oxidative stress and is caused by cyanide triggering a calcium-
dependent massive release of EAA transmitters. The acidosis 
induced by the extracellular accumulation of EAAs is linked to 
the worsening of cerebral infarction, in part from the restoration 
of oxidative metabolism following the oxidative stress and from 
neurotoxicity via EAA activation of NMDA receptors.43
Increased intracellular calcium and loss  
of calcium homeostasis
Cyanide causes a sustained increase in intracellular calcium, 
which leads to apoptosis,44 with the extent of neuron death 
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increasing with time of exposure. Cyanide-induced   calcium 
increases are greater than those induced by glutamate 
because cyanide also induces the release of calcium from 
intracellular pools.45 However, cyanide neurotoxicity is not as 
extensive as that of glutamate, which indicates that a general 
  elevation in cytoplasmic calcium does not necessarily predict 
  neurodegeneration.45 The finding that cyanide induces a 32% 
increase in brain mitochondrial calcium levels supports the 
hypothesis that calcium plays an important role in cyanide-
mediated neurotoxicity, although the magnitude of the initial 
intracellular calcium concentration change does not predict 
the toxicity of an agonist on NMDA receptors.46,47
Neuroprotection
Single techniques acting alone
Hypothermia
Hyperthermia leads to neurotoxicity, in part by causing 
  neuroinflammation.14 Hypothermia provides neuroprotection 
by preventing the development of hyperthermia.
Clinically, whole-body and whole or localized brain 
hypothermia provide neuroprotection against infarct-induced 
oxidative stress.48 It also provides neuroprotection against 
compromised blood flow and reperfusion.49 Whole-body 
hypothermia provides only limited neuroprotection, probably 
because it requires interactions with additional   environmental 
factors. Localized hypothermia (32°C)   provides good 
  neuroprotection during periods of compromised cerebral blood 
flow and oxygen delivery.49 Different studies show that the tem-
perature that provides best neuroprotection varies   considerably 
from mild (33°C–35°C)50 to moderate (30°C–32°C),51 severe 
(27°C–29°C),51 and extreme (20°C).52
The first phase of neuroprotection by hypothermia is 
by reducing excitatory synaptic activity, which reduces the 
release and accumulation of excessive EAAs, reduces toxic 
extracellular acidification,53 and induces the   expression of 
heat shock proteins.54 Hypothermia to 33°C reduces NMDA 
channel activation,50 thereby reducing NMDA receptor-
mediated excitatory postsynaptic potential   amplitude.55 
Simultaneously, the activated channel open time is shortened, 
thereby reducing calcium influx and preventing the disruption 
of calcium homeostasis. The neuroprotection provided by 
hypothermia is enhanced when combined with the simul-
taneous infusion of NMDA receptor antagonists,56 and the 
neuroprotection provided by hypothermia is increased 23-fold 
when combined with alkalinization.57
Mild hypothermia causes a 50-fold reduction in H2O2 
production, which allows neurons to retain their normal 
cell morphology and viability.58 Whole-brain hypothermia   
(below 35°C) impairs brain tissue oxygenation but provides 
neuroprotection by reducing the metabolic rate of neurons 
and thus their oxygen requirement59 while maintaining 
slightly better energy levels.60 Thus, the toxicity of   oxidative 
stress is reduced by hypothermia by reducing adenosine 
triphosphate breakdown more than its synthesis, leading 
to improved   neuron survival, which means that secondary 
failures in energy requirements are prevented.61 Hypothermia 
also causes ischemic neurons to significantly increase 
their expression of the antiapoptotic protein bcl-2.62 Thus, 
  hypothermia lowers the risk of oxidative stress-induced 
cellular damage and programmed cell death by increasing 
the activity of glutathione-peroxidase due to the induced 
expression of the antiapoptotic protein bcl-2.62
Hypothermia during and after a period of oxygen-glucose 
deprivation and brief exposure to a high concentration of the 
NMDA or glutamate provide neuroprotection by reducing the 
release of glutamate and other EAAs into the   extracellular 
space, thus reducing their excessive accumulation and 
the development of extracellular acidification, inhibiting 
  excessive NMDA receptor activation, and shortening the 
NMDA receptor open channel time.50 These actions also 
minimize calcium influx through the open channel, thus 
preventing the disruption of calcium homeostasis.63
Hypothermia to 10°C improves the long-term survival 
of rats following hemorrhagic shock by decreasing tissue 
oxygen consumption and by altering the expression profiles 
of key genes, with an overall upregulation of prosurvival 
pathways and a downregulation of metabolic pathways.64
One concern about the clinical use of severe hypothermia 
(cooling to below 30°C) is that it may be harmful to neurons, 
their circuits, or support cells. However, experiments on the 
spinal cord of large mammals (rabbits and pigs) show that 
reducing the temperature of the spinal cord to 4°C for more 
than 30 minutes during complete ischemia does not cause 
the loss of neurons or their viable neuronal circuits, which 
would otherwise undergo massive loss if the spinal cord was 
maintained at higher temperatures.49
Alkalinization
Alkalinization provides neuroprotection against ischemia-
induced acidification caused by the excessive release and 
accumulation of EAAs and excessive NMDA receptor activa-
tion.65,66 Alkalinization to pH 8.2 protects adult rat CNS neurons 
against ischemic effects of infarct,67 and mouse neocortical 
neurons in primary culture from azide-induced chemical 
anoxia.68 Further, alkalinization of adult human   dorsal root 
ganglion (DRG) neurons provides   neuroprotection against 
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glutamate and   acidification, with   neuroprotection increasing 
as pH increases from 7.6 to 9.3.69
Oxidative stress-induced ischemia leads to rapid   intracellular 
acidification,70 with the extent of neuron death being related to 
the degree and duration of   extracellular   acidosis.32   Extracellular 
pH changes result in similar   intracellular pH shifts in DRG 
neurons.71 Oxidative stress-induced acidosis and death of 
cultured primary mouse neocortical neurons is prevented by 
alkalinization to pH 8.2.68 Alkalinization of adult rat CNS 
and adult human DRG neurons also provides neuroprotection 
against prolonged ischemia,6 with   alkalinization to pH 8.2 
preventing the development of acidosis-induced neurotoxicity 
against azide-induced chemical anoxia.68 However, it is not 
known whether alkalinization acts by preventing EAA-induced 
acidosis or blocking the actions of glutamate.66
Alkalinization provides neuroprotection against increased 
intracellular calcium by changing the relative concentration 
of soluble extracellular calcium, which is pH dependent. 
Calcium requires a pH of ,6 to enter solution, whereas at 
physiological pH 7.6, calcium solubility is 160 mg/L and 
increases to 6390 mg/L at pH 7.0. However, its solubility 
decreases 40-fold to 10.1 gm/L at pH 8.4.72 Thus, although 
decreasing intracellular pH leads to increased calcium solu-
bility and neurotoxicity, alkalinization provides neuroprotec-
tion against cyanide toxicity by causing calcium precipitation 
into calcium bicarbonate, thus reducing the concentration 
of soluble extracellular calcium available to enter neurons.73 
Similarly, removing intracellular calcium by chelation with 
1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid 
partially reduces cyanide-induced neurotoxicity.74
NMDA receptors are pH sensitive with acidification 
resulting in (1) excessive calcium entry75 and neurotoxic 
increases in intracellular calcium,68 (2) the release of   calcium 
from intracellular stores,76 and (3) the loss of   calcium 
  homeostasis.69 However, alkalinization from pH 7.6 to pH 
8.7 provides neuroprotection by reducing NMDA receptor 
activation and excess accumulation of neurotoxic   intracellular 
calcium.75
Ischemia and cyanide induce the generation of neurotoxic 
NO free radicals. Free-radical formation can be prevented by 
intracellular alkalinization to pH 7.4 during the initial 30 minutes 
of NO exposure.77 Therefore, extracellular alkalinization, which 
induces intracellular alkalinization, provides neuroprotection by 
reducing the production of oxygen free radicals.
Adenosine
Adenosine is a nucleoside rapidly formed in large amounts by 
neurons and glial cells during ischemia due to the   intracellular 
breakdown of adenosine triphosphate. The adenosine is 
transported into the extracellular space, where it provides 
endogenous neuroprotection by counteracting the   generation 
of the neurotoxic increases in the extracellular calcium con-
centration.78 Administration of the adenosine A2A agonists 
during prolonged spinal cord ischemia exerts neuroprotec-
tion,79 and this neuroprotection is increased when combined 
with hypothermia.80
Adenosine provides neuroprotection by suppressing the 
neurotoxic gamma-aminobutyric acid (GABA)-activated 
  current in a majority of the neurons (77%).81 Similarly, 
regional hypothermia together with the simultaneous   infusion 
of an NMDA receptor antagonist enhances the neuroprotec-
tion provided by hypothermia.56 When hypothermia and 
alkalinization are applied simultaneously, they provide 
greater neuroprotection to ischemic adult rat DRG neurons 
than either one alone.82
Neuroprotection  by  adenosine  agonists  results 
from   ischemia inducing the upregulation of adenosine 
A2A   receptors (A2A-R).79 If adenosine A2A-R induction 
is blocked, perfusion with adenosine A2A agonists does 
not provide neuroprotection, reduce reperfusion-  associated 
inflammation, reduce paralysis, or reduce neuronal   apoptosis.79 
Thus, A2A-R agonists exert their neuroprotective effects by 
activating the induced neuronal A2A-R upregulated during 
spinal cord reperfusion.79 However, the earlier the perfusion 
with the A2A receptor agonist is initiated after the start of 
ischemia, the greater the neuroprotection that is provided.83
Adenosine A1 receptor agonists or inhibitors of cellular 
reuptake and inactivation of adenosine provide neuroprotec-
tion against glutamate-induced excitotoxicity by   blocking cal-
cium influx mediated by the NMDA receptor and   preventing 
the loss of intracellular calcium   homeostasis.84 A1 adenosine 
receptor activation suppresses neural   activity by a predomi-
nantly presynaptic action,85 probably by directly stabilizing 
the neuronal membrane potential by increasing the conduc-
tance for potassium and chloride ions. This blocks glutamate 
induction of an uncontrolled membrane depolarization via ion 
channel-linked glutamate receptors of the NMDA type.86 This 
blocks voltage-sensitive   potassium currents, increases NMDA 
receptor-mediated calcium influx, and impairs glutamate 
uptake by astrocytes.87 Adenosine appears to provide neuro-
protection by suppressing the neurotoxic GABA-activated 
current in a majority of the neurons (77%).81
Neurotrophic factors
The neurotrophic factors nerve growth factor88,89 and brain-
derived neurotrophic factor90 facilitate brain tissue repair 
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  following experimental traumatic brain injury such as 
  ischemia by stimulating increases in neuronal metabolism, 
cell size, and process outgrowth.91
Neuropeptides
A number of neuropeptides provide neuroprotection. 
  Cortistatin, a neuropeptide with endocrine activities 
in humans, provides neuroprotection against bacterial 
  infection.92 Neuropeptide Y provides dopaminergic cell 
neuroprotection against 6-hydroxydopamine-induced toxic-
ity in vitro and in animal models of Parkinson’s disease.93 
Neuronal damage caused by excess activation of NMDA 
is blocked by the neuropeptide apelin via its activation of 
G-protein-coupled receptors by modulating neuronal pro-
survival pathways and/or NMDA receptor signaling.94 The 
neuropeptide galanin, which is upregulated in the brain of 
patients with Alzheimer’s disease, provides neuroprotection 
against amyloid-ß toxicity and other excitotoxic injuries, by 
activating the second galanin receptor subtype.95
Plasticity
Biological organisms evolved to be able to respond to 
stress with plasticity that promotes neuroprotection and cell 
  survival. One example of plasticity to stress is the plasticity 
of astrocytes, which following injury can produce glial scar 
tissue that inhibits axon regeneration but can also release 
factors that at the same injury site provide neuroprotection 
and support axonal regeneration.96 Another example is the 
amyloid precursor protein (APP), which, under stress, such 
as Alzheimer’s disease, is not cleaved, leading to its   triggering 
neurodegeneration. However, under   physiological   conditions, 
APP is processed by the nonamyloidogenic pathway, lead-
ing to secreted N-terminal APP fragment, which provides 
neuroprotection, synaptic plasticity, neurite outgrowth, and 
synaptogenesis.97 Finally, aging is associated with low-grade 
neuroinflammation, including microglia activation, which 
appears to contribute to deficits in neural plasticity and cogni-
tive function. However, mice subjected to stress in the form 
of exercise by wheel running show a decrease in microglia 
activation but an increase in microglia-expressing insulin-like 
growth factor-1, which provides neuroprotection.98
Precondition
Preconditioning neurons to various compounds causes a 
reprogramming of mitochondrial biology to those noxious 
stress stimuli, which leads to both increased   mitochondrial 
and neuronal tolerance against neurodegenerative events.99,100 
Hypoxic preconditioning provides   neuroprotection against 
subsequent hypoxia, in part by inhibiting neuronal 
  apoptosis.101 The neuroprotection is caused by the precon-
ditioning hypoxia, leading to an increased production of the 
delta opioids receptor (DOR) and the DOR ligand L-ENK. 
DOR activation following hypoxic preconditioning is 
responsible for providing enhanced neuroprotection against 
subsequent ischemia.101 Hypoxia-induced neuroprotection 
is also associated with hypoxia-inducible factor-1-α, which 
regulates astrocyte iron metabolism and transport, and by 
hypoxia preconditioning changing the expression of iron 
metabolism proteins.102
Erythropoietin
Beyond their hematopoietic functions, blood progenitor 
cells release the growth factors erythropoietin,   granulocyte 
colony-stimulating factor, and thrombopoietin, which provide 
  neuroprotection while also promoting neuronal growth.103–105
Stem cells
Implantation of stem cells provides neuroprotection. 
  Following an optic nerve crush, many axotomized retinal 
ganglion cells die due to a lack of target-derived neurotrophic 
factors. But the delivery of bone-marrow mononuclear 
cells provides neuroprotection and increases both retinal 
ganglion cell survival and axon outgrowth.106 Similarly, 
mesenchymal stem cells transplanted into the rat brain reduce 
  ischemia-induced brain damage in rats by inducing a marked 
increase in the synthesis of neurotrophic factors such as vas-
cular endothelial growth factor, epidermal growth factor, and 
basic fibroblast growth factor in the host brain.107 Another 
example is the implantation of human umbilical cord blood 
cells, which provide neuroprotection against neurological 
deficits in both in vitro and in vivo models of ischemic brain 
injuries, potentially by reducing inflammation and trophic 
actions and enhancing angiogenesis.108
Cell lines
The transplantation of HMO6, a human microglial cell line, 
provides neuroprotection following ischemia by reduc-
ing gliosis and neuroinflammation, and by enhancing the 
production of neurotrophic factors from endogenous and 
transplanted cells.109
Multiple techniques acting simultaneously
As discussed previously, hypothermia, alkalinization, and 
adenosine each applied singly provides neuroprotection 
against the consequences of trauma. However, additional 
evidence shows that the simultaneous application of these 
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techniques enhances the neuroprotection they provide in both 
clinical and animal model studies.
Hypothermia plus alkalinization
The neuroprotection against prolonged ischemia provided by 
hypothermia (20°C) and alkalinization (pH 9.3) combined 
is by approximately three-fold greater than when they are 
applied singly.82
Hypothermia and NMDA receptor antagonists
Regional hypothermia together with the simultaneous 
infusion of an NMDA receptor antagonist enhances the 
  neuroprotection provided by hypothermia.56
Hypothermia and adenosine A2A receptor agonists
The neuroprotection provided by localized hypothermia against 
45 minutes of ischemia is increased by the   simultaneous local 
infusion with adenosine.80 However, neuroprotection is even 
greater when the local perfusion of the ischemic spinal cord 
with hypothermic saline is combined with the systemic infu-
sion of an adenosine A2A receptor agonist.110
Conclusion
Traumas trigger neurotoxicity by different mechanisms, 
among which are the massive release of EAAs, acidifica-
tion, excessive activation of NMDA receptors, the massive 
intracellular increase in calcium, loss of calcium homeosta-
sis, oxidative stress, and lipid peroxidation, each causing 
neurotoxicity by separate mechanisms. Although different 
techniques singly provide neuroprotection against each of 
these neurotoxic triggers, no one method provides neuro-
protection against all the other neurotoxic events that occur 
simultaneously as well as sequentially. Strong evidence sug-
gests that hypothermia, alkalinization, and adenosine provide 
greater neuroprotection than that produced by any alterna-
tive neuroprotective techniques. However, the simultaneous 
application of these three techniques provides significantly 
greater neuroprotection than that of any one alone. Further 
evidence suggests that their neuroprotection can be even 
further enhanced when they are combined with additional 
methods, such as administration of glucocorticoids. Finally, 
it must be stressed that to be optimally effective these neu-
roprotective techniques must be applied within the “golden 
hour” of a trauma, before the different neurotoxic cascades 
are triggered and become irreversible.
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